N-acetylcysteine for therapy-resistant tobacco use disorder: a pilot study

Prado, Eduardo, Maes, Michael, Piccoli, Luiz Gustavo, Baracat, Marcela, Barbosa, Décio Sabattini, Franco, Olavo, Dodd, Seetal, Berk, Michael and Vargas Nunes, Sandra Odebrecht 2015, N-acetylcysteine for therapy-resistant tobacco use disorder: a pilot study, Redox report, doi: 10.1179/1351000215Y.0000000004.

Attached Files
Name Description MIMEType Size Downloads

Title N-acetylcysteine for therapy-resistant tobacco use disorder: a pilot study
Author(s) Prado, Eduardo
Maes, Michael
Piccoli, Luiz Gustavo
Baracat, Marcela
Barbosa, Décio Sabattini
Franco, Olavo
Dodd, Seetal
Berk, MichaelORCID iD for Berk, Michael orcid.org/0000-0002-5554-6946
Vargas Nunes, Sandra Odebrecht
Journal name Redox report
Publisher Maney Publishing
Place of publication Edinburgh, Scotland
Publication date 2015-03
ISSN 1743-2928
Keyword(s) Depression
Glutathione.
Inflammation
N-Acetylcysteine
Oxidative stress
Smoking cessation
Summary Introduction N-Acetylcysteine (NAC) may have efficacy in treating tobacco use disorder (TUD) by reducing craving and smoking reward. This study examines whether treatment with NAC may have a clinical efficacy in the treatment of TUD. Methods A 12-week double blind randomized controlled trial was conducted to compare the clinical efficacy of NAC 3 g/day versus placebo. We recruited 34 outpatients with therapy resistant TUD concurrently treated with smoking-focused group behavioral therapy. Participants had assessments of daily cigarette use (primary outcome), exhaled carbon monoxide (COEXH) (secondary outcome), and quit rates as defined by COEXH<6 ppm. Depression was measured with the Hamilton Depression Rating Scale (HDRS). Data were analyzed using conventional and modified intention-to-treat endpoint analyses. Results NAC treatment significantly reduced the daily number of cigarettes used (Δ mean±SD = -10.9 ± 7.9 in the NAC-treated versus -3.2 ± 6.1 in the placebo group) and COEXH (Δ mean± SD = -10.4 ± 8.6 ppm in the NAC-treated versus -1.5 ± 4.5 ppm in the placebo group); 47.1% of those treated with NAC versus 21.4% of placebo-treated patients were able to quit smoking as defined by COEXH<6 ppm. NAC treatment significantly reduced the HDRS score in patients with tobacco use disorder. Conclusions These data show that treatment with NAC may have a clinical efficacy in TUD. NAC combined with appropriate psychotherapy appears to be an efficient treatment option for TUD.
Language eng
DOI 10.1179/1351000215Y.0000000004
Field of Research 110319 Psychiatry (incl Psychotherapy)
Socio Economic Objective 920410 Mental Health
HERDC Research category C1 Refereed article in a scholarly journal
Copyright notice ©2015, Maney Publishing
Persistent URL http://hdl.handle.net/10536/DRO/DU:30070216

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 18 times in TR Web of Science
Scopus Citation Count Cited 17 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 266 Abstract Views, 8 File Downloads  -  Detailed Statistics
Created: Wed, 04 Mar 2015, 11:05:58 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.